Takeda Acquires Nycomed For US$13.7bn

BMI View: Takeda's acquisition of Nycomed will aid the company's expansion into the high growth, emerging pharmaceutical markets, boosting the company's revenue stream and protecting it from Prevacid (lansoprazole) revenue losses and the expiry of the patent for blockbuster diabetes drug Actos (pioglitazone hydrochloride), due in

To read the full article, please choose one of the following options: